Your browser is no longer supported. Please, upgrade your browser.
BMY Bristol-Myers Squibb Company weekly Stock Chart
Bristol-Myers Squibb Company
IndexS&P 500 P/E14.49 EPS (ttm)3.16 Insider Own0.10% Shs Outstand1.63B Perf Week-4.23%
Market Cap74.79B Forward P/E10.32 EPS next Y4.44 Insider Trans0.12% Shs Float1.63B Perf Month-2.22%
Income5.17B PEG2.73 EPS next Q1.06 Inst Own80.10% Short Float6.10% Perf Quarter-5.32%
Sales23.29B P/S3.21 EPS this Y28.70% Inst Trans6.39% Short Ratio6.45 Perf Half Y-8.13%
Book/sh9.31 P/B4.92 EPS next Y6.20% ROA15.10% Target Price56.10 Perf Year-16.99%
Cash/sh5.36 P/C8.53 EPS next 5Y5.32% ROE37.30% 52W Range44.30 - 63.69 Perf YTD-11.95%
Dividend1.64 P/FCF28.65 EPS past 5Y14.50% ROI25.40% 52W High-29.04% Beta0.76
Dividend %3.58% Quick Ratio1.80 Sales past 5Y6.60% Gross Margin71.10% 52W Low2.02% ATR1.11
Employees23300 Current Ratio1.90 Sales Q/Q14.00% Oper. Margin27.80% RSI (14)40.55 Volatility2.49% 1.95%
OptionableYes Debt/Eq0.40 EPS Q/Q12.90% Profit Margin22.10% Rel Volume1.00 Prev Close45.77
ShortableYes LT Debt/Eq0.37 EarningsJul 25 BMO Payout51.10% Avg Volume15.45M Price45.20
Recom2.30 SMA20-3.70% SMA50-3.22% SMA200-11.41% Volume8,040,762 Change-1.26%
May-28-19Initiated Goldman Buy
May-20-19Downgrade Argus Buy → Hold
May-03-19Upgrade Barclays Equal Weight → Overweight $53 → $55
May-03-19Resumed JP Morgan Overweight $62
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Jun-26-19 11:00AM  Big Pharma Has to Bet Big on M&A. Investors Dont. Bloomberg
11:00AM  AbbVie to Buy Allergan: Prescribed ETFs Zacks
09:26AM  AbbVie to Acquire Allergan in Nearly $62B Cash & Stock Deal Zacks
09:22AM  The Zacks Analyst Blog Highlights: AbbVie, Allergan, Bristol-Myers and Celgene Zacks
Jun-25-19 05:45PM  Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know Zacks
04:15PM  AbbVie + Allergan: Where Are The Synergies? Zacks
03:56PM  Bristol-Myers to Sell Otezla for Celgene Merger, Shares Down Zacks
09:35AM  Company News For Jun 25, 2019 Zacks
Jun-24-19 08:06PM  Traders Still Avoiding Small Caps Investopedia -7.42%
04:55PM  What Happened in the Stock Market Today Motley Fool
04:29PM  US STOCKS-S&P 500 slips as healthcare drags, investors eye G20 summit Reuters
04:26PM  Stocks End Mixed as Wall Street Looks to G-20 Summit for U.S.-China Trade Talks
04:23PM  Why These Innovative Biotech ETFs Soaring Zacks
04:14PM  Celgene Told To Divest Blockbuster Drug And Other Bad News For Bristol Investor's Business Daily
03:51PM  Bristol-Myers Squibb Company -- Moody's: Bristol's Otezla divestiture credit negative Moody's
03:47PM  5 Top Stock Trades for Tuesday: CELG, BMY, CZR InvestorPlace
02:27PM  US STOCKS-Wall Street struggles for direction ahead of G20 summit Reuters
01:14PM  Bristol-Myers Slips As Regulatory Hiccups Delay Celgene Deal; Liver Cancer Study Faces Setback Benzinga
01:12PM  US STOCKS-Wall St flat as healthcare losses limit tech gains Reuters
12:20PM  Bristol-Myers Continues to Show Bottoming Price Action on the Charts
12:03PM  Bristol-Myers Will Divest Celgene Blockbuster to Close Deal Bloomberg
11:31AM  Bristol-Myers's $74 Billion Celgene Splurge Just Got Riskier Bloomberg
11:29AM  US STOCKS-Wall St edges higher as tech gains more than offset healthcare losses Reuters
10:54AM  Bristol-Myers plans to divest Celgene's psoriasis drug Reuters
10:52AM  Bristol-Myers Plans Otezla Sale to Win FTC Approval for $74 Billion Celgene Deal
10:39AM  US STOCKS-Wall Street edges higher as tech offsets healthcare loss Reuters
10:04AM  To allay FTC concerns, Bristol-Myers to sell Celgene psoriasis treatment American City Business Journals
09:09AM  US STOCKS-Wall Street set to open higher with trade talks in focus Reuters
09:00AM  Bristol-Myers Squibb Stock Is Falling as Celgene Deal Is Delayed
08:14AM  UPDATE: Bristol-Myers offers update on liver cancer trial, to sell Otezla to hasten close of Celgene deal MarketWatch
07:43AM  UPDATE 2-Bristol-Myers plans to divest Celgene's psoriasis drug Reuters
07:14AM  Bristol to divest Celgene's psoriasis treatment in FTC clearance push Reuters
06:59AM  Bristol-Myers Squibb Provides Update on Pending Merger with Celgene Business Wire
06:59AM  Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma Business Wire
04:23AM  Stocks - Caesars Entertainment, Deere Rise Premarket; Spotify, Bristol-Myers Falls
Jun-22-19 09:33AM  This would be the worst-case scenario for health stocks, according to UBS MarketWatch
Jun-21-19 10:01AM  3 Big Biotechs Hold Growth Potential in Second Half of 2019 Zacks
09:07AM  Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod Zacks
08:00AM  Where Will bluebird bio Be in 1 Year? Motley Fool
Jun-20-19 09:05AM  What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them? Motley Fool
Jun-19-19 11:04AM  The Zacks Analyst Blog Highlights: Broadcom, Amgen, NVIDIA, Bristol-Myers and Restaurant Brands Zacks
09:06AM  Big Drugmakers That May Tread the M&A Path After Pfizer Zacks
09:00AM  Bristol-Myers (BMY) Upgraded to Buy: What Does It Mean for the Stock? Zacks
08:45AM  3 Reasons Why Growth Investors Shouldn't Overlook Bristol-Myers (BMY) Zacks
06:59AM  Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy Business Wire
Jun-18-19 05:45PM  Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know Zacks
02:11PM  2019 Business of Pride honorees: Bristol-Myers Squibb American City Business Journals
01:00PM  Top Analyst Reports for Broadcom, Amgen & NVIDIA Zacks
09:51AM  Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio Zacks
Jun-17-19 09:35AM  Pfizer Expands in Cancer With $10.6 Billion Deal for Array Bloomberg
Jun-16-19 09:00AM  Is It Too Late to Buy Celgene Stock? Motley Fool
Jun-14-19 01:52PM  Should Bristol-Myers Squibb Company (NYSE:BMY) Be Part Of Your Dividend Portfolio? Simply Wall St.
12:06PM  3 Big Pharma Stocks to Buy Right Now Zacks
08:29AM  Mallinckrodt Presents Encouraging Data on Acthar Gel for RA Zacks
06:59AM  Bristol-Myers Squibb Presents Updated Efficacy Data from Phase 2 Trial of Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Business Wire
Jun-13-19 05:40PM  Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris Zacks
04:38PM  Bristol-Myers Squibb Announces Dividend Business Wire
04:30PM  New Mechanistic Study Explores the Relationship Between a Key Genetic Marker and Clinical Efficacy of ORENCIA® (abatacept) or adalimumab in Moderate-to-Severe Early Rheumatoid Arthritis Patients Business Wire
04:12PM  Amgen, Biogen, Gilead and Novo Nordisk have very high capacity for M&A, says Moodys MarketWatch
09:19AM  Price target on Bristol-Myers stock cut to $51 at UBS MarketWatch
Jun-12-19 06:33PM  Roche's Rituxan Gets Priority Review for Blood Disorder Zacks
06:21PM  Novartis Reports Data on Cosentyx for Psoriatic Arthritis Zacks
05:45PM  Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know Zacks
10:19AM featured highlights include: CDW, Bristol-Myers, Celgene, PepsiCo and Northrop Zacks
09:15AM  Bristol-Myers Squibb (BMY) is a Top Dividend Stock Right Now: Should You Buy? Zacks
08:28AM  Boost Your Portfolio's Health With These 3 Big Drug Stocks Zacks
Jun-11-19 06:16PM  Insys Down on Bankruptcy News Amid Increasing Legal Expenses Zacks
09:14AM  FDA Greenlights Merck's Blockbuster Drug Keytruda For First-Line Treatment Of Head, Neck Cancer Benzinga
08:53AM  Merck (MRK) to Buy Private Biotech Tilos for Up to $773M Zacks
08:34AM  Top 5 ROE Stocks to Buy as US-Mexico Trade Concerns Abate Zacks
Jun-10-19 12:34PM  Sanofi (SNY) in Focus: Stock Moves 5.5% Higher Zacks
09:57AM  The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca Zacks
Jun-07-19 01:06PM  2 Dividend Stocks to Buy That Are Better Than 3M Stock InvestorPlace
12:05PM  Seth Klarman's Favorite Biotech Positions
10:21AM  Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache Zacks
09:09AM  Novartis Appoints New Pharma Unit Head, Gives Other Updates Zacks
Jun-06-19 07:17PM  Management Changes Intended to Boost Bristol-Myers Squibb After Celgene Deal
05:45PM  Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know Zacks
04:56PM  Celgene & Acceleron's BLA for Luspatercept Accepted by FDA Zacks
04:41PM  Mallinckrodt Down After Agreement with DOJ for Litigation Zacks
03:13PM  5 Healthcare Stocks to Pick Up From the Wreckage InvestorPlace
01:55PM  Top 5 Stocks in the Fight Against Cancer Motley Fool
09:09AM  Was ASCO Quieter for Big Drug/Biotech Stocks This Year? Zacks
06:59AM  Bristol-Myers Squibb to Announce Results for Second Quarter 2019 on July 25, 2019 Business Wire
Jun-05-19 04:30PM  The Celgene Merger Looks Secure So Why Is Bristol Under Pressure? Investor's Business Daily
03:11PM  Cancer-Fighting Stocks & ETF: What You Need to Know Zacks
01:16PM  Hedge Funds Have Never Been This Bullish On Bristol Myers Squibb Company (BMY) Insider Monkey
12:09PM  Merger uncertainty and impending trials for Bristol-Myers leave investors in limbo MarketWatch
11:46AM  Bristol-Myers Is Getting Bigger. Investors Arent Impressed.
09:00AM  Celgene (CELG) Presents Data on Pipeline Candidates at ASCO Zacks
06:59AM  Bristol-Myers Squibb Announces Post-Closing Leadership Team Business Wire
Jun-04-19 04:24PM  Here's Another Checkmark For Bristol's Looming Celgene Takeover Investor's Business Daily
12:23PM  Bristol-Myers Squibb to Take Part in Goldman Sachs 40th Annual Global Healthcare Conference Business Wire
10:32AM  Aduro Stock Crashes After ASCO Updates on Cancer Candidate Zacks
10:19AM  Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity Zacks
10:18AM  Merck's Antibiotic Zerbaxa Gets FDA Nod for New Indication Zacks
09:03AM  Bristol-Myers (BMY) Presents Multiple Data on Opdivo at ASCO Zacks
04:24AM  China to Audit Sanofi, Bristol-Myers in Drugmaker Accounts Probe Bloomberg
Jun-03-19 02:46PM  Why Cancer-Fighting Stocks & ETFs Are Soaring Zacks
02:15PM  Five-Year Survival Observed in Longest Follow-up to Date of Advanced Melanoma Patients Treated with the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab) Business Wire
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Samuels Theodore R. IIDirectorMay 16Buy47.295,000236,44027,000May 20 04:36 PM
Santiago Karen MurphyControllerMay 16Sale47.563,065145,7713,066May 20 04:37 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400373,239May 06 04:40 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0011,594025,816Apr 05 04:32 PM
Dubow AdamChief Compliance & Ethics OffiMar 10Option Exercise0.003,735018,240Mar 13 07:41 AM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00173,4190422,683Mar 13 07:40 AM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0062,2550411,547Mar 13 07:39 AM
Biondi PaulSVP, Head of Strategy & BDMar 10Option Exercise0.008,61907,860Mar 13 07:39 AM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0019,9250141,077Mar 13 07:38 AM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0026,568063,652Mar 13 07:37 AM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMar 10Option Exercise0.005,864021,343Mar 13 07:36 AM
Santiago Karen MurphyControllerMar 10Option Exercise0.003,82506,850Mar 13 07:37 AM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0045,1700558,854Mar 13 07:35 AM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0025,577081,508Mar 13 07:34 AM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0014,180092,626Mar 13 07:42 AM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0015,707014,501Mar 13 07:41 AM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise17.5152,884925,999392,690Mar 04 04:42 PM
LEUNG SANDRAEVP, General CounselFeb 28Option Exercise17.51169,8932,974,826634,478Mar 04 04:42 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerFeb 02Option Exercise0.004,46504,465Feb 05 04:53 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010206,117Dec 04 04:31 PM
Biondi PaulSVP, Head of Strategy & BDOct 02Option Exercise0.005920592Oct 04 04:56 PM
Dubow AdamChief Compliance & Ethics OffiSep 03Option Exercise0.00797015,495Sep 05 04:49 PM
Santiago Karen MurphyControllerSep 01Option Exercise0.0064104,057Sep 05 04:49 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510050,168Aug 03 05:05 PM
Biondi PaulSVP, Head of Strategy & BDJul 01Option Exercise0.001,46101,461Jul 03 09:24 PM